$NVIDIA (NVDA.US)$
In the datacenter business: revenue increased by 112% year-on-year to $30.8 billion.
In the gaming division: revenue increased by 15% year-on-year to $3.3 billion.
In the professional visualization division: revenue increased by 17% to $0.486 billion.
In the automobiles and robotics division: revenue increased by 72% to $0.449 billion.
Nvidia's stock price has tripled year-to-date, but the current price-to-earnings ratio (P/E) is around 34 times next year's analyst estimates, and the price/earnings growth ratio (PEG) is 0.85. Generally, a PEG ratio of less than 1 is considered undervalued, so Nvidia's stock price is at an attractive level.

$NVIDIA (NVDA.US)$ After the closing of the US stock market on November 20th, Earnings for the third quarter of fiscal year 2025are scheduled to be announced.A comeback by former president Trumpriding the wave of a stock market rally on the 7threached a new all-time high,Will this earnings announcement further push up the stock price?
On the next business day after the earnings reports, what will be the closing price of nvidia stock? Let's predict the closing price and vote!
【Compensation】
● Distribute 10,000 points
At 10:30 PM on November 21st (Japan time)By the deadline, nvidia's Closing price on November 21st (6 AM on November 22nd Japan time) Predict the closing price and select from the price ranges below. If the actual closing price falls within the range you voted for, points will be equally distributed to all users who voted in that range (Example: If 50 users hit the target range, each will earn 200 points!)
[Hit Challenge! 1,000 yen Amazon gift card]
Predict the closing price of nvidia accurately and seize the chance to get additional benefits!
On November 21st...

1st place @ひぽ株
Today $JIADE (JDZG.US)$ $BIO-key International (BKYI.US)$
Shareholding. Profit and loss ratio 221.58%
2nd place @芝浦メカトロニクス
$Greenlane (GNLN.US)$ $Healthcare Triangle (HCTI.US)$ $Regencell Bioscience (RGC.US)$ $Evoke Pharma (EVOK.US)$ $Iterum Therapeutics (ITRM.US)$ I have a shareholding.
Ranking 3rd @ジョニー0306
$BIO-key International (BKYI.US)$ $Greenlane (GNLN.US)$ $Healthcare Triangle (HCTI.US)$ $Autonomix Medical (AMIX.US)$ $Evoke Pharma (EVOK.US)$ $ImmunityBio (IBRX.US)$ $Iterum Therapeutics (ITRM.US)$ $Upexi (UPXI.US)$ $Virax Biolabs (VRAX.US)$ $Genprex (GNPX.US)$
...

Currently, the financial markets are filled with dynamic price movements.Japan-U.S. stock earnings seasonNow that the official start of the earnings season for Japan-U.S. stocks has begun, are you all ready? This is the perfect time to take advantage of the abundant features on the moomoo app.Abundant featuresThis is a great opportunity to utilize the rich features on the moomoo app to aim for improved investment performance! Let's continue to challenge together for better results!
List of Functions:
Earnings Calendar & Earnings List, Japanese subtitle translation, AI automatic summarization, Analyst Ratings & Morningstar Ratings, AI Stock Price Predictions
Catch the earnings information quickly
Earnings Calendar & Earnings List
Since earnings announcement dates tend to have a significant impact on stock prices, first of all,Understanding the earnings date and timeis important. The "Earnings Calendar" provides the dates and times of companies' earnings announcements ina calendar formatIt is a convenient tool that can be checked.
In the Earnings Summary, you can check the latest quarterly earningsnews. You can check.Detailed earnings reports, earnings call (conference call) information, andView analysis and interpretationYou can do it.
Path 1: Market Tab > Japanese Stocks/US Stocks > "Performance" > "Earnings Calendar"
Path 2: Moo Tab > Premium > "Earnings Summary"
If you want to know more, click here to check.
...

$Tesla (TSLA.US)$ The stock price dropped by about 9% in post-event trading, showing the largest decline among S&P 500 index ETF. Many analysts are analyzing this decline, and it is believed that the reason is that the event's content was not seen as immediately profitable. In particular, the absence of the low-priced 'Model 2' announcement was one of the factors that disappointed investors' expectations.
However, many analysts believe that Tesla continues to lead the market and see the recent stock price decline as an opportunity.
Additionally, whether Tesla's robotaxi business can achieve full self-driving capability depends on the technological advancements and regulatory trends in the coming years. Investors need to focus on the long-term growth potential without being swayed by short-term market reactions.
We are optimistic about the possibility of the stock price rebounding to its highest level in the next year. With the announcement of new models and successful updates to FSD, investor expectations will rise, leading to an increase in stock prices.